Nkarta, Inc.
NKTXNasdaq
$2.60
0.0%Jul 17 close · end-of-day
Price
1Y↑ +42.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$193.1M
Enterprise Value
-$37.4M
P/E
—
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-45.8%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$99.9M
Free Cash Flow (TTM)
-$88.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-35.0%
ROIC
-165.8%
Debt / Equity
—
Net Cash
$230.4M
Return 1Y
+30.0%
Company profile
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens.
- CEO
- Paul J. Hastings
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 140
- Headquarters
- California
- Website
- nkartatx.com
Management & directors
- Hastings Paul JChief Executive Officer
- Mahmood NadirPresident
- Rose Shawn MarshallSee Remarks
Roles derived from SEC Form 4 filings.
Earnings
NKTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.37↓ -14.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$51.5M | -$86.4M | -$119.0M | -$131.7M | -$128.2M | -$122.0M |
| Net income | -$91.4M | -$86.1M | -$113.8M | -$117.5M | -$108.8M | -$104.1M |
| Diluted EPS | — | -$2.62 | -$2.61 | -$2.40 | -$1.60 | -$1.41 |
| Operating cash flow | -$43.5M | -$67.9M | -$57.0M | -$86.2M | -$99.7M | -$88.7M |
| Free cash flow | -$51.0M | -$73.0M | -$104.1M | -$114.3M | -$104.1M | -$89.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$30.7M | -$33.8M | -$30.9M | -$36.6M | -$27.2M | -$27.3M | -$31.0M | -$30.9M |
| Net income | -$25.0M | -$28.3M | -$25.9M | -$32.0M | -$23.0M | -$21.7M | -$27.4M | -$27.8M |
| Diluted EPS | -$0.34 | -$0.39 | -$0.29 | -$0.43 | -$0.31 | -$0.29 | -$0.38 | -$0.37 |
| Operating cash flow | -$21.9M | -$24.5M | -$24.8M | -$29.6M | -$18.8M | -$18.7M | -$21.6M | -$28.2M |
| Free cash flow | -$24.2M | -$25.3M | -$25.9M | -$30.1M | -$18.9M | -$18.7M | -$22.2M | -$28.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 26, 2026
May 14, 2026
May 12, 2026
Apr 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | HASTINGS PAUL J· Chief Executive Officer | Sale | 1,776 | $2.71 | $4,812.96 | filing |
| 2026-01-15 | HASTINGS PAUL J· Chief Executive Officer | Sale | 26,046 | $2.07 | $53,915.22 | filing |
| 2026-01-15 | Mahmood Nadir· President | Sale | 5,649 | $2.07 | $11,693.43 | filing |
| 2026-01-06 | Rose Shawn Marshall· See Remarks | Award | 70,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | Mahmood Nadir· President | Award | 80,000 | $0.00 | $0.00 | filing |
| 2026-01-06 | HASTINGS PAUL J· Chief Executive Officer | Award | 94,000 | $0.00 | $0.00 | filing |
| 2025-06-18 | HASTINGS PAUL J· Chief Executive Officer | Sale | 1,790 | $1.79 | $3,204.10 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.